Sanofi Launches 'Once Daily' Oral, Teriflunomide 14 mg Tablet 'Aubagio'- for Treatment of Multiple Sclerosis in India

/ -- - Aubagio (Teriflunomide, 14 mg) offers patients diagnosed with Multiple Sclerosis the efficacy and convenience of once-a-day oral treatment
- Over 200,000 people in India are living with Multiple Sclerosis[1]
(Logo: https://mma.prnewswire.com/media/793372/Sanofi_Genzyme_Logo.jpg )
(Photo: https://mma.prnewswire.com/media/793371/Aubagio_Teriflunomide_14_mg.jpg )
Commenting on the launch, N. Rajaram, Managing Director, Sanofi India, said, "There are around two lakh people living with this disease in India. There are increasing numbers of cases being detected due to greater awareness and access to better diagnostic facilities. Millions of patients depend on us for their healthcare needs, and as a health journey partner, we understand the many challenges that people with Multiple Sclerosis face."

He added, "For over a decade Sanofi has invested in developing and delivering novel therapeutic solutions for treatment of Multiple Sclerosis around the world; and with that, we have now brought our original research product to India. This product has the potential to offer an efficacious and convenient treatment regimen of just once a day oral tablet, vis--vis common treatment options that are injectables. With Aubagio (Teriflunomide, 14 mg), we reiterate Sanofi Genzyme's commitment to improve and empower the lives of people with debilitating diseases in India."

Dr. Shalini Menon, Head - Medical Affairs, India & South Asia, Sanofi, said, "Aubagio (Teriflunomide, 14 mg) is a differentiated disease modifying therapy, that blocks the enzyme involved in multiplication of overactive immune cells. When taken daily, Aubagio (Teriflunomide, 14 mg) reduces the number of overactive immune cells that cause the disease flare-ups, while still allowing normal immune cell activity to occur. It is important to note that Aubagio (Teriflunomide, 14 mg) has demonstrated consistent efficacy in reducing the frequency of relapses, delaying the accumulation of physical disability and, arresting further decrease in brain volume. In addition, given its convenience as an oral medicine, Aubagio (Teriflunomide, 14 mg) encourages people with Multiple Sclerosis to continue with long-term treatment."

About Multiple Sclerosis:
Multiple Sclerosis is an autoimmune, debilitating disease of the nervous system that affects the spinal cord and brain. In Multiple Sclerosis, there is progressive damage to the sheath that protects nerve cells, impairing communication between the brain and the nervous system. Signs and symptoms vary from one person to another and may include: weakness and numbness in the limbs, poor vision, tingling and pain in parts of the body, unsteady gait, lack of coordination, fatigue or slurred speech. Most people develop a 'relapsing-remitting' form of Multiple Sclerosis where symptoms ('relapses') may last for days or weeks and then improve completely or partially. This is then followed by a period of remission that could last for months or even years.[2]Multiple Sclerosis is a common cause of disability that usually affects young persons during their most productive years but only 45% of all patients are correctly diagnosed.[4] Research shows across the world, over 2.3 million people are living with Multiple Sclerosis.[5]

About Aubagio (Teriflunomide, 14 mg)
About Sanofi
[1] http://www.mssocietyindia.org/: Accessed on July 4, 2018 (This was in the context of - Currently, in almost 90% cases , Multiple Sclerosis treatment is driven by injectables)
[3] Genzyme data on File
[4] Genzyme data on File (As per market research done in 2015)